CJC-1295 + Ipamorelin research and evidence overview

The research evidence for CJC-1295 + ipamorelin is real at the component level and empty at the product level. CJC-1295 with DAC has randomized human pharmacokinetic data; ipamorelin has a rigorous characterization and one published human efficacy trial, which failed. Pairing a GHRH analog with a ghrelin-receptor agonist is well supported in humans — using a different peptide, intravenously, as a diagnostic test. What does not exist is a study of these two peptides together.

• Discovery and chemistry (rats, 2005). ConjuChem made three maleimido derivatives of human GRF(1-29) to defeat the parent peptide's very short half-life. The winner, CJC-1295, is a tetra-substituted GRF(1-29) carrying an Nε-3-maleimidopropionamide lysine at the C-terminus that conjugates to Cys34 of serum albumin — giving a 4-fold increase in GH area-under-the-curve over two hours versus plain hGRF(1-29), and plasma presence beyond 72 hours (Jetté, Endocrinology 2005).

• Human pharmacokinetics (2006). Two randomized, placebo-controlled, double-blind ascending-dose trials in healthy adults aged 21–61, over 28 and 49 days. A single subcutaneous injection raised mean plasma GH 2- to 10-fold for six or more days and IGF-1 1.5- to 3-fold for 9–11 days; after multiple doses IGF-1 stayed above baseline up to 28 days. Estimated half-life was 5.8–8.1 days, with no serious adverse reactions (Teichman, JCEM 2006). Nearly every marketing claim traces back to this paper. It measured hormones, not outcomes.

• Phase 2 and program termination (2005–2006). A 12-week randomized, placebo-controlled phase 2 study in HIV-associated visceral obesity, enrolling 120 patients, is recorded as terminated (NCT00267527). FDA's later review states the sponsor "withdrew CJC-1295 DAC from clinical trials in 2006 after the death of a subject involved in a phase 2 trial" (FDA PCAC briefing, December 2024). Development did not resume.

FDA's own calibration: the human studies "were conducted in healthy adults, had small sample sizes, and were of short duration despite the substance being nominated to treat a chronic condition," and it identified no effectiveness data for any CJC-1295 form.

• Original characterization (1998). Ipamorelin was introduced as "the first GHRP-receptor agonist with a selectivity for GH release similar to that displayed by GHRH." In rats and conscious swine its GH potency was very similar to GHRP-6, but at doses more than 200-fold above the ED50 it did not release ACTH or cortisol at levels different from GHRH stimulation, and no secretagogue tested affected FSH, LH, prolactin, or TSH (Raun, Eur J Endocrinol 1998). Preclinical — and the origin of every "ipamorelin is the selective one" claim.

• Phase 2 in postoperative ileus (2014). A multicentre, double-blind, placebo-controlled trial in bowel-resection patients (117 enrolled, 114 analysed) gave 0.03 mg/kg intravenous ipamorelin twice daily from postoperative day 1 through day 7 or discharge. The primary endpoint, time to tolerating a standardized solid meal, was not met: 25.3 versus 32.6 hours, p=0.15, with no significant differences in secondary analyses either (Beck, Int J Colorectal Dis 2014). This is ipamorelin's only published human efficacy trial, and development stopped.

The strongest argument the blend has rests on two human studies that used neither of these peptides.

In 18 normal men, GHRP-6 at 0.1, 0.3, and 1.0 µg/kg by intravenous bolus raised GH dose-dependently, and submaximal doses combined with 1 µg/kg GHRH "stimulated GH release synergistically," leading the authors to conclude the two act through independent mechanisms (Bowers, JCEM 1990). That synergy became a clinical tool: in 125 adults with pituitary disease and 125 healthy controls, the combined GHRH+GHRP-6 test produced mean peak GH of 59.2 µg/L versus 4.1 µg/L, outperforming the insulin tolerance test (Popovic, Lancet 2000).

Three differences keep this from being evidence for the product: the secretagogue was GHRP-6, not ipamorelin; the route was intravenous; and the purpose was a single provocation lasting minutes. A test designed to maximise a diagnostic GH peak is not a template for chronic therapy.

There is no published randomized trial, no observational study, and no registered clinical trial of CJC-1295 administered with ipamorelin. No study has measured lean mass, fat mass, strength, sleep, recovery, or adverse events for the pairing in humans.

What fills that vacuum is marketing. FDA's review documented clinic websites asserting that combining ipamorelin with CJC-1295 delivers a "3-5 fold increase in growth hormone release over ipamorelin alone," and a subject-matter expert describing a "'trending' synergistic combination of ipamorelin acetate with CJC-1295" (FDA PCAC briefing, October 2024). No source is offered for the multiple, because none exists.

Neither peptide is approved anywhere, and in 2024 both were rejected for legal compounding use in the United States. FDA proposed excluding all five CJC-1295 forms and both ipamorelin forms from the 503A Bulks List, citing poor characterization, inconsistent naming, safety concerns, and no effectiveness data. Its advisory committee agreed: ipamorelin voted down 12–0 with one abstention in October (minutes), CJC-1295 (free base) unanimously 13–0 in December (minutes). Both are also named individually on the WADA Prohibited List under S2.2.4 — CJC-1295 among GHRH analogues, ipamorelin among growth hormone secretagogues — prohibited at all times as non-Specified Substances.

Three questions resolve most of the confusion here. Did the study use the combination or one component? Always one component. Which CJC-1295 — the DAC molecule from the human trials, or the short-acting no-DAC peptide in most vials? The published human data covers only the former. And was the endpoint a hormone concentration or a clinical outcome? Across this class, hormone endpoints succeed and clinical endpoints do not.

See also the CJC-1295 + Ipamorelin overview and the component pages for ipamorelin and CJC-1295 with DAC.